Rakesh Jhunjhunwala Portfolio: Jubilant Pharmova stock up over 3% as billionaire investor increases stakes in March 2022 quarter

Billionaire investor Rakesh Jhunjhunwala has picked up extra shares in a pharma company Jubilant Pharmova Limited as per the March 2022 shareholding pattern available on the BSE. 

Rakesh Jhunjhunwala holds 57,50,000 equity shares, which translates into a 3.61 per cent stake in Jubilant Pharmova during the March quarter, the shareholding pattern of the company showed.  

See Zee Business Live TV Streaming Below:

In the December quarter, the ace investor 50,00,000 shares, which aggregates to a 3.14 per cent stake in the company, as per the shareholding on the BSE.  

Jhunjhunwala has increased about 7,50,000 shares in the company, which comes to a nearly 0.5 per cent increase in the overall holding of the renowned investor. 

Along with Rakesh his wife Rekha Jhunjhunwala too holds around 3.15 per cent stakes (50,20,000 shares) in Jubilant Pharmova. She has been stayed put in the stock during the March quarter. 

Rakesh Jhunjhunwala, who is termed as the Big Bull of the Indian stock market, along with his wife and other associates publicly holds 35 stocks with a net worth of over Rs 33,129.4 crore, as per the stock analysis website trendlyne.com. 

On Tuesday, Jubilant Pharmova shares gained over 4.5 per cent on the BSE intraday trade. At around 02:25 pm, the counter was trading over 3 per cent on the BSE as compared to a 0.48 per cent rise in the S&P BSE Sensex.  

The stock in the last month has gained almost 6 per cent and has witnessed a correction of around 25 and 42 per cent in the past 6- and 12-months period on the BSE. 

So far in the March quarter, the ace investor has bought extra shares in Canara Bank and stayed put in Titan Company and Delta Corp. While he has trimmed his stakes in Aptech, Escorts and Wockhardt, as per terndlyne.com. 

The fourth quarter of the financial year 2021-22 is expected to be a flattish quarter for most Pharma companies, as per domestic brokerage firm Nirmal Bang, expecting that a few companies to benefit from the US market.